Strides Pharma Science Ltd (STAR) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Strides Pharma Science (Strides), headquartered in Bengaluru, India, is a global pharmaceutical company specialising in the development and manufacturing of niche finished dosage formulations. With a primary focus on intellectual property-led products, Strides has emerged as one of the world’s leading producers of soft gelatin capsules. Operating in several countries, Strides maintains a robust global manufacturing presence with facilities spread across four continents, including some sites approved by the US FDA.

The company’s product portfolio encompasses a diverse range of technically complex pharmaceutical offerings, such as liquids, creams, ointments, soft gels, sachets, tablets, and modified-release dosage formats. The company excels in manufacturing products that are traditionally challenging to produce. Moreover, the company boasts a dedicated research and development facility in India equipped with global filing capabilities, enabling continuous innovation and expansion.

Driven by a resolute commitment to quality, Strides has gained a significant competitive edge in an evolving regulatory landscape. By implementing advanced quality standards supported by an ITdriven platform, the company ensures consistent and stringent adherence to the highest quality measures across all manufacturing locations.

Business area of the company

The company is a global pharmaceutical company that develops, manufactures, and markets a wide range of high-quality, affordable generic medicines. The company’s diverse portfolio spans complex generics across multiple dosage forms including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. With its agile R&D, end-to-end integration, and a strong global distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets.

Awards

2017-18

• Received several customer award including the Cardinal Health Supply Chain Excellence Award for 2017

2019-20

• The Global Presence Award
• Foreign owned business Award

Milestones

• 1990: Incorporation of Strides as 'Strides Pharmaceuticals Private Limited' in Bombay; began as a trading company.
• 1991: Shifted base to Bangalore and began building early manufacturing capabilities.
• 1992: First exports to Nigeria; marked the beginning of Strides’ presence in Africa.
• 1993: Laid groundwork for regulatory compliance and built early supplier networks.
• 1994: Became a public company; name changed to 'Strides Pharmaceuticals Limited'; fund raising from Schroders, Venture Capital.
• 1995: Partnered with Pharmagel (Italy) to set up a softgel facility at KR Suresh Gardens (KRSG), in Bangalore.
• 1996: Acquired Remed Labs; MoU with Plama Laboratories, a Mangalore Listed entity; also initiated tablet & capsule facility at KRS Gardens.
• 1997: Name changed to 'Strides Arcolab Limited'; to reflect joint venture with Arcolab SA, Switzerland.
• 1998: Commissioned first softgel facility at KRSG in Bengaluru.
• 1999: Revenue crossed Rs 100 crore; acquired Caryl Labs and Global Remedies.
• 1999: entered the LATAM market via Brazil.
• 1999: established GCC presence through Pentagon Exim. 
• 1999: Completed three-way merger with Plama Laboratories (specialty chemicals) and Remed Laboratories (sterile injectables).
• 2000: Listed on National Stock Exchange and Regional Stock Exchanges; launched domestic generics division; acquired Arcolab, Geneva.
• 2001: Merged Bombay Drugs & Pharma Limited (BDPL) with Strides; consolidated operations in APIs.
• 2002: Expanded in LATAM with acquiring stake in Solara S.A. De C.V, Infabra, and Cellofarma Ltd., set up manufacturing plants in Brazil & Mexico; Arcolab became 100% subsidiary.
• 2003: Entered JV with Ribbon, Italy for cephalosporins; hived off CRAMs division; began development for AIDS, TB, Malaria.
• 2004: Listed on Bombay Stock Exchange; partnered with Akorn, USA for sterile products; restructured LATAM holdings.
• 2005: Launched Star Technology and Research (STAR) Global R&D centre in Bengaluru; crossed Rs 500 crore revenue; issued $40 million via Foreign Currency Convertible Bond.
• 2006: Acquired stake in Beltapharm (Italy), DHA Singapore, and Arcolab facilities in Poland; entered into Clinton Foundation AIDS supply alliance.
• 2007: Raised $100 million via zero-coupon bonds; acquired Grandix Pharma and Farma Plus (Norway); oncology JV with Aspen. Acquired Diaspa S.p.A, a USFDA approved fermentation facility, stake in Strides Vital Nigeria Limited, Nigeria.
• 2008: Revenue crossed Rs 1,000 crore; signed global supply deal with GlaxoSmithKline Pharmaceuticals (GSK) for emerging markets; acquired controlling stake in Genepharm Australasia (later renamed Ascent Pharmahealth), making Strides the fourth-largest generics player in Australia.
• 2009: Launched critical care division ‘Ray of Life’; restructured into Pharma and Specialty; launched Starflu for H1N1.
• 2010: Revenue crossed Rs 1,500 crore; entered oncology tie-up with Pfizer; rebranded injectable business as Agila; acquired Inbiopro entering biologics space.
• 2011: Divested Australia business to Watson for AUD 375 million; expanded Agila to Malaysia; extended Pfizer licensing to emerging markets.
• 2012: Partnered with Gilead & Eli Lilly; raised funds from Proparco for African expansion; acquired sterile facility in Hosur, Tamil Nadu.
• 2013: Divested Agila to Mylan for $1.6B; declared Rs 630/share dividend; rebranded biotech business as Stelis Biopharma.
• 2014: Merged Stelis with Inbiopro; brought in GMS Holdings as investor in Stelis; acquired branded India assets from Bafna.
• 2015: Merged with Shasun to form Strides Shasun; re-entered Australia through Arrow; expanded India portfolio with CNS brands from Sun Pharma and J&J; and strengthened Sub-Saharan presence via Medispan and Universal Corp., gaining a rare WHO PQ facility.
• 2016: Arrow signed 10-year alliance with Pharmacy Alliance; exited CRAMS UK; acquired PediaCare brand.
• 2017: Exited probiotics and Africa generics; demerged API business as Solara; formed JV with Vivimed for US market. Divested India Brands Business to Eris Life Sciences, including transfer of stake in Strides Healthcare Private Limited.
• 2018: Renamed as Strides Pharma Science Ltd; divested Strides Chemicals to Solara; partnered with ILS for Consumer Health division.
• 2019: Acquired Florida facility; entered China via JV; acquired Fairmed Healthcare, Switzerland.
• 2020: Merged Arrow, Remedies & Strides EM business; Stelis raised $195 million; began exports of Favipiravir during COVID.
• 2021: Acquired Chestnut Ridge facility, along with basket of ANDAs from Endo International Plc., USA; launched Stripiravir (Molnupiravir); partnered with MPP for global COVID drugs.
• 2022: Stelis received EU-GMP; Universal Kenya received WHO PQ; EMA approval for Kauliv biosimilar.
• 2023: Partnered with Orbicular for nasal sprays; Stelis divested Unit 3 to Syngene; consolidated South Africa operations under Trinity.
• 2024: Merged Strides Alathur into parent; demerged CDMO & softgel biz into OneSource.
• 2025: Listed OneSource on National Stock Exchange & Bombay Stock Exchange as specialty CDMO.
• 2025: Celebrated 35 years of Strides. 
• 2025: Crossed Rs 4,565 crore revenue & Rs 802 crore EBITDA.
• 2025: Created over Rs 115 billion shareholder value; reinforced global pharma position.